SABCS

First comparison of targeted sentinel node assessment shows no difference in recurrence rates

In phase III trial, capivasertib benefited patients with or without AKT pathway alterations

Camizestrant also led to meaningful PFS improvements in those with detectable ESR1 mutations

Prior therapy, baseline mutations confound results; "intriguing" benefit with PD-L1 inhibitor

Study suggests no increased risk of cancer recurrence versus historical control

Trastuzumab deruxtecan improves survival in second- and later-line settings

Response rates on the order of 58-68%, with or without endocrine therapy

No improvement in the overall analysis but a hint of benefit in premenopausal patients

Low score suggests improved outcomes with ovarian suppression plus adjuvant endocrine therapy

Doubling of PFS could be death knell for combination chemotherapy in difficult-to-treat subgroup

Density of cellular complex after neoadjuvant therapy tied to cancer subtypes, may be targetable

No clear explanation for responses to HER2-targeted drug in HER2-negative tumors

Objective response rate of 42% in patients previously treated with CDK4/6 inhibitors

Progression-free survival doubled with treatment change based on monitoring for resistance marker